西利亚德公司用于实体瘤的新型嵌合抗原受体 T 细胞疗法。
Celyad's novel CAR T-cell therapy for solid malignancies.
机构信息
Celyad, Mont-Saint-Guibert, Belgium.
Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
出版信息
Curr Res Transl Med. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4.
PMID:29625833
Abstract
Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors.
摘要
Celyad 最近启动了几项临床试验，使用的是 CYAD-01 产品，这是一种基于自然杀伤细胞组 2D（NKG2D）的嵌合抗原受体（CAR），用于治疗实体瘤和血液系统肿瘤。本文讨论了 CYAD-01 的独特特性，期望为治疗实体瘤提供一种新的范式。
Zotero 插件